LSF emodepside (BAY 44-4400) or matching placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Filariasis
Conditions
Filariasis
Trial Timeline
Nov 14, 2017 → Oct 15, 2018
NCT ID
NCT03383614About LSF emodepside (BAY 44-4400) or matching placebo
LSF emodepside (BAY 44-4400) or matching placebo is a phase 1 stage product being developed by Bayer for Filariasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03383614. Target conditions include Filariasis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03383614 | Phase 1 | Completed |
Competing Products
2 competing products in Filariasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AWZ1066S + Placebo | Eisai | Phase 1 | 33 |
| Emodepside (BAY 44-4400) | Bayer | Phase 1 | 30 |